Spinocerebellar Ataxia Type 31 Exacerbated by Anti-amino Terminal of Alpha-enolase Autoantibodies.

anti-amino terminal of alpha-enolase antibody autoimmune cerebellar ataxia hashimoto's encephalopathy immune-mediated cerebellar ataxia spinocerebellar ataxia

Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
2022
Historique:
entrez: 14 9 2022
pubmed: 15 9 2022
medline: 17 9 2022
Statut: ppublish

Résumé

We herein report a 61-year-old woman who was genetically diagnosed with spinocerebellar ataxia type 31 whose symptoms were modified by anti-amino terminal of alpha-enolase (NAE) antibodies, known as a biomarker of Hashimoto's encephalopathy (HE), and ultimately responded to immunotherapy. The relative titers of anti-NAE antibodies increased when her cerebellar ataxia showed acute deterioration and decreased after immunotherapy. This is the first report of cerebellar ataxia associated with genetic spinocerebellar ataxia with concomitant cerebellar type HE. Physicians should be mindful of measuring anti-NAE antibodies to prevent overlooking patients with genetic spinocerebellar ataxia with treatable simultaneous ataxic diseases.

Identifiants

pubmed: 36104177
doi: 10.2169/internalmedicine.8883-21
pmc: PMC9556240
doi:

Substances chimiques

Autoantibodies 0
Phosphopyruvate Hydratase EC 4.2.1.11

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2793-2796

Références

Mov Disord. 2008 Jul 30;23(10):1370-7
pubmed: 18546342
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Cerebellum. 2017 Apr;16(2):518-524
pubmed: 27830516
J Neuroimmunol. 2005 May;162(1-2):130-6
pubmed: 15833368
Eur Neurol. 2013;69(1):14-20
pubmed: 23128836
Cell Mol Life Sci. 2001 Jun;58(7):902-20
pubmed: 11497239
J Neuroimmunol. 2007 Apr;185(1-2):195-200
pubmed: 17335908
Neurology. 1991 Feb;41(2 ( Pt 1)):228-33
pubmed: 1992366
Am J Hum Genet. 2009 Nov;85(5):544-57
pubmed: 19878914

Auteurs

Satoshi Zeniya (S)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.

Nobuo Sanjo (N)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.

Hiroya Kuwahara (H)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.

Kinya Ishikawa (K)

The Center for Personalized Medicine for Healthy Aging, Tokyo Medical and Dental University, Japan.

Miwa Higashi (M)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.

Akiko Matsunaga (A)

Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan.

Makoto Yoneda (M)

Faculty of Nursing and Social Welfare Sciences, Fukui Prefectural University, Japan.

Hidehiro Mizusawa (H)

National Center Hospital, National Center of Neurology and Psychiatry, Japan.

Takanori Yokota (T)

Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH